Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $472.78 Consensus PT from Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given a consensus rating of “Moderate Buy” by the twenty-six brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $472.7848.

Several analysts have issued reports on the company. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Chardan Capital restated a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. HC Wainwright restated a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $308.51 on Friday. The firm has a market cap of $41.16 billion, a PE ratio of 180.42 and a beta of 0.39. The stock’s fifty day moving average price is $321.95 and its two-hundred day moving average price is $379.57. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals has a 1 year low of $245.96 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). The firm had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.65) earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post 6.75 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the business’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares in the company, valued at approximately $6,989,297.80. The trade was a 7.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Tolga Tanguler sold 1,598 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $523,584.70. Following the sale, the executive vice president owned 36,606 shares in the company, valued at approximately $11,993,955.90. The trade was a 4.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 38,656 shares of company stock valued at $12,370,696. 0.86% of the stock is currently owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Mediolanum International Funds Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $11,389,000. Rakuten Investment Management Inc. purchased a new position in Alnylam Pharmaceuticals during the third quarter worth about $14,205,000. Generali Asset Management SPA SGR increased its stake in Alnylam Pharmaceuticals by 6,368.0% in the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after acquiring an additional 3,184 shares during the last quarter. Cerity Partners LLC increased its stake in Alnylam Pharmaceuticals by 171.2% in the 3rd quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company’s stock worth $12,507,000 after acquiring an additional 17,316 shares during the last quarter. Finally, CWM LLC increased its stake in Alnylam Pharmaceuticals by 431.3% in the 3rd quarter. CWM LLC now owns 29,287 shares of the biopharmaceutical company’s stock worth $13,355,000 after acquiring an additional 23,775 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.